Topical HDAC inhibitor shows activity in MFApril 13, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
FDA grants priority review to sBLA for blinatumomabMarch 31, 2017Leukemia, Myelodysplasia, TransplantationPharmacyALL
Drug receives orphan designation for AMLMarch 29, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
CHMP recommends drug for relapsed/refractory cHLMarch 25, 2017Lymphoma & Plasma Cell DisordersPharmacyHodgkin LymphomaAggressive Lymphomas
New resource designed to help prevent CINVMarch 23, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaHematology NursingPharmacyRelated Issues
FDA approves pembrolizumab to treat cHLMarch 15, 2017Lymphoma & Plasma Cell DisordersPharmacyHodgkin LymphomaAggressive Lymphomas
Selinexor trials placed on partial holdMarch 14, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyAMLNon-Hodgkin LymphomaAggressive Lymphomas
Drug granted priority review for relapsed/refractory AMLMarch 2, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
FDA expands approved indication for lenalidomideFebruary 28, 2017Multiple MyelomaPharmacyTransplantation
CHMP recommends authorization of antiemetic agentFebruary 27, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyRelated Issues
